CG Oncology, Inc. Share Price & Technical Analysis
CGON · $64.25 (-0.53%)
Healthcare / Biotechnology
$64.25
-0.53%
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinica…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 3 years shown)
-2% return in May, -12% avg return in past 3 year May month.
54% return in 2026, 33% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 26% | 14% | 19% | -2% | -2% | – | – | – | – | – | – | – | 54% |
| 25 | 4% | -11% | -5% | 11% | -5% | 0% | 3% | 3% | 51% | 8% | 5% | -6% | 57% |
| 24 | 29% | 20% | -4% | -8% | -20% | -4% | 6% | 12% | 4% | -5% | -3% | -18% | 10% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.18B
P/E ratio
—
52W high
$75.50
52W low
$23.65
Volume
6,52,816
Beta
0.42
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is CG Oncology, Inc. share price today?
- CG Oncology, Inc. (CGON) last traded around $64.25 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CGON have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CGON. Download the app for real-time alerts.
- How can I analyze CG Oncology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.